Thalidomide as initial therapy for early-stage myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Thalidomide as initial therapy for early-stage myeloma

Published:2003-04 Issue:4 Volume:17 Page:775-779
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Rajkumar S V,Gertz M A,Lacy M Q,Dispenzieri A,Fonseca R,Geyer S M,Iturria N,Kumar S,Lust J A,Kyle R A,Greipp P R,Witzig T E

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2402866.pdf

Reference32 articles.

1. Jemal A, Thomas A, Murray T, Thun M . Cancer statistics, 2002. Ca Cancer J Clin 2002; 52: 23–47.

2. Kyle RA, Greipp PR . Smoldering multiple myeloma. N Engl J Med 1980; 302: 1347–1349.

3. Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R . Risk of disease progression in asymptomatic multiple myeloma. Am J Med 1993; 94: 57–61.

4. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R . Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000; 96: 2037–2044.

5. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR . Current therapy for multiple myeloma. Mayo Clin Proc 2002; 77: 813–822.

Cited by 204 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions;Pharmaceuticals;2024-07-06

2. A review of chemotherapeutic drugs-induced arrhythmia and potential intervention with traditional Chinese medicines;Frontiers in Pharmacology;2024-03-20

3. Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials;Clinical Lymphoma Myeloma and Leukemia;2023-01

4. Mechanisms Contributing to Acquired Activated Protein C Resistance in Patients Treated with Thalidomide: A Molecular Dynamics Study;Cardiovascular & Hematological Disorders-Drug Targets;2022-12

5. Inhibition of Wnt Signaling in Colon Cancer Cells via an Oral Drug that Facilitates TNIK Degradation;Molecular Cancer Therapeutics;2022-10-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3